Change in ONSD at M3 and M6 was not associated with the treatment group, but with ONSD at baseline (M3: \(\beta\)= 0.69, 95% CI 0.99, 0.39
The FDA has raised concerns about the safety and effectiveness of compounded medications, particularly in light of several reports of adverse events linked to their use
However: Wegovy is dosed at a higher level (up to 2.4 mg/week), which may lead to faster or greater weight loss
Sarcopenia-related muscle wasting impairs physical performance and functional capacity, leading to difficulties in daily activities, such as walking, stair climbing, and lifting objects [50, 103]
Studies examining glutathione levels across the human lifespan reveal a marked decline in both brain and blood concentrations as we age, particularly after age 40 [1]
10.1001/archpsyc.61.6.618 259